Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
Cacabelos, R.; Fernández-Novoa, L.; Martínez-Bouza, R.; McKay, A.; Carril, J.C.; Lombardi, V.; Corzo, L.; Carrera, I.; Tellado, I.; Nebril, L.; Alcaraz, M.; Rodríguez, S.; Casas, Á.; Couceiro, V.; Álvarez, A. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals 2010, 3, 3040-3100. https://doi.org/10.3390/ph3103040
Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, McKay A, Carril JC, Lombardi V, Corzo L, Carrera I, Tellado I, Nebril L, Alcaraz M, Rodríguez S, Casas Á, Couceiro V, Álvarez A. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals. 2010; 3(10):3040-3100. https://doi.org/10.3390/ph3103040
Chicago/Turabian StyleCacabelos, Ramón, Lucía Fernández-Novoa, Rocío Martínez-Bouza, Adam McKay, Juan C. Carril, Valter Lombardi, Lola Corzo, Iván Carrera, Iván Tellado, Laura Nebril, Margarita Alcaraz, Susana Rodríguez, Ángela Casas, Verónica Couceiro, and Antón Álvarez. 2010. "Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants" Pharmaceuticals 3, no. 10: 3040-3100. https://doi.org/10.3390/ph3103040